Zenas BioPharma (ZBIO) Total Liabilities (2023 - 2026)

Zenas BioPharma's Total Liabilities history runs 4 years deep, the most recent figure standing at $411.9 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 732.88% year-over-year to $411.9 million; the TTM figure through Mar 2026 stood at $411.9 million (up 732.88% YoY), while the FY2025 annual figure was $141.5 million, up 146.04% from the prior year.
• Total Liabilities was $411.9 million for Q1 2026 at Zenas BioPharma, up from $141.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $411.9 million in Q1 2026 to a low of $43.8 million in Q4 2023.
• Historically, Total Liabilities has averaged $151.9 million across 4 years, with a median of $125.6 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Liabilities tumbled 81.49% in 2025, then jumped 732.88% in 2026.
• A 4-year view of Total Liabilities shows it stood at $43.8 million in 2023, then surged by 31.26% to $57.5 million in 2024, then jumped by 146.04% to $141.5 million in 2025, then surged by 191.07% to $411.9 million in 2026.
• The last three Total Liabilities figures came in at $411.9 million (Q1 2026), $141.5 million (Q4 2025), and $125.6 million (Q3 2025), per Business Quant data.